title: Editorial Commentary: Fosfomycin: The Current Status of the Drug.
authors.affiliation: Alfa Institute of Biomedical Sciences Department of Internal Medicine-Infectious Diseases, Iaso General Hospital, Iaso Group, Athens, Greece Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts.
authors.forename: Matthew E
authors.initials: ME
authors.lastname: Falagas
authors.affiliation: Alfa Institute of Biomedical Sciences Department of Internal Medicine, Athens Medical Center, Athens Medical Group, Greece.
authors.forename: Petros I
authors.initials: PI
authors.lastname: Rafailidis
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D005578:Fosfomycin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011472:Prostatitis / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D005578:Fosfomycin
keywords: Enterobacteriaceae; Escherichia coli; fosfomycin; multidrug-resistant; prostatitis